1428 ET [Dow Jones]--Doximity's first-quarter earnings beat shows that its added services are drawing physicians to its platform, which is known as the "LinkedIn for doctors," and pharma ad spending could soon follow, says Mizuho analyst Steven Valiquette. The company's newsfeed reached a record number of users while its AI tool utilization multiplied by five. The company is also seeing strong engagement for AI Scribe, a patient note-taking tool it launched last week. Doximity will "attract greater biopharma digital marketing spend as the app is now reaching rapidly higher and broader levels of physician engagement," Valiquette said. The stock was up 12% to $65.30 Friday. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
August 08, 2025 14:31 ET (18:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.